AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10511608 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with omeprazole (20 mg twice daily), amoxicillin (1000 mg), and clarithromycin (500 mg) for 14 days
Number of subjects: 337
Study 10511608 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 337
Study 10511608 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 337
Study 10511608 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment and H. pylori-negative patients
Number of subjects: 337
Study 10511608 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment and H. pylori-positive patients
Number of subjects: 337
Study 8822429 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and oxidized regenerated cellulose barrier (Interceed group, n = 25)
Number of subjects: 50
Study 8822429 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group, n = 25)
Number of subjects: 50
Study 2379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with mental handicap (Down's syndrome)
Number of subjects: 382
Study 2379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with mental handicap (epilepsy)
Number of subjects: 382
Study 2379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dentate adults with mental handicap
Number of subjects: 382
Study 2379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with mental handicap
Number of subjects: 382
Study 2379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with Down's syndrome
Number of subjects: 382
Study 7381554 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan performed at the end of the surgical procedure
Number of subjects: 0
Study 7381554 — intervention group
Group type: EXPERIMENTAL
Intervention: CT assessments before initiating radio-chemotherapy and at the completion of each cycle
Number of subjects: 0
Study 30178187 — intervention group
Group type: EXPERIMENTAL
Intervention: Small tidal volume (STV) ventilation (3-5 mL/kg)
Number of subjects: 58
Study 30178187 — intervention group
Group type: COMPARATOR
Intervention: Large tidal volume (LTV) ventilation (6-8 mL/kg)
Number of subjects: 58
Study 30178187 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) of 5 cm H2O
Number of subjects: 58
Study 30178187 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP) of 0 cm H2O
Number of subjects: 58
Study 27789115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg orally
Number of subjects: 40
Study 27789115 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg orally
Number of subjects: 40
Study 27789115 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 25393080 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin/hypothermia group (N=15; received hypothermia and five daily enteral doses of melatonin 10 mg kg(‐1))
Number of subjects: 45
Study 25393080 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin/hypothermia group
Number of subjects: 45
Study 25393080 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia group (N=15; received 72‐h whole‐body cooling)
Number of subjects: 45
Study 24412265 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-drop stimulator (FDS; Bioness L300) used for ambulation over 42 weeks after 8 physical therapy sessions
Number of subjects: 99
Study 24412265 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-drop stimulator (FDS; Bioness L300)
Number of subjects: 99
Study 24412265 — intervention group
Group type: COMPARATOR
Intervention: No FDS used
Number of subjects: 99
Study 22456475 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 373
Study 22456475 — intervention group
Group type: COMPARATOR
Intervention: Right‐ventricle‐to‐pulmonary‐artery shunt
Number of subjects: 373
Study 19447844 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 29
Study 19447844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 17270006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (single dose)
Number of subjects: 80
Study 17270006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg and esomeprazole 40 mg (single doses)
Number of subjects: 80
Study 17270006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (5 days' dosing)
Number of subjects: 80
Study 17270006 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg vs. rabeprazole 10 mg (5 days' dosing)
Number of subjects: 80
Study 17270006 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (general)
Number of subjects: 80
Study 15650984 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac/paracetamol
Number of subjects: 60
Study 15650984 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 60
Study 15650984 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 11786584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin added to hormonal therapy (arm 1)
Number of subjects: 37
Study 11786584 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone (arm 2)
Number of subjects: 37
Study 11786584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin-related toxicity
Number of subjects: 37
Study 9538979 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 92
Study 9538979 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 92
Study 9538979 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 8011354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat stitch during wound closure
Number of subjects: 300
Study 8011354 — intervention group
Group type: COMPARATOR
Intervention: No fat stitch during wound closure
Number of subjects: 300
Study 2595326 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Number of subjects: 31
Study 2595326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1099047 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent administration of naloxone (N-allylnoroxymorphone) 500-2000 mg daily
Number of subjects: 0
Study 1099047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31828863 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germ (WG) supplementation, 20g daily for 12 weeks
Number of subjects: 80
Study 31828863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31191789 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPER‐500® (deep heating device)
Number of subjects: 38
Study 31191789 — intervention group
Group type: COMPARATOR
Intervention: SonoStim® (ultrasound)
Number of subjects: 38
Study 28549131 — intervention group
Group type: EXPERIMENTAL
Intervention: I-wave protocol (4.3 ms interstimulus interval)
Number of subjects: 32
Study 28549131 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (3.5 ms interstimulus interval)
Number of subjects: 32
Study 25397691 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL) + Propranolol (PP)
Number of subjects: 66
Study 25397691 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 66
Study 23239836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 3196
Study 23239836 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AVP levels
Number of subjects: 3196
Study 21670711 — intervention group
Group type: EXPERIMENTAL
Intervention: HIKCUPS intervention (6-month obesity intervention)
Number of subjects: 160
Study 19543080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day) at bedtime
Number of subjects: 238
Study 19543080 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (30 mg/day) upon awakening
Number of subjects: 238
Study 16314017 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right cerebral damage
Number of subjects: 34
Study 16314017 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 15286880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin IV followed by oral administration
Number of subjects: 56
Study 15286880 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone IV alone or in combination with erythromycin IV, followed by clarithromycin PO
Number of subjects: 56
Study 11269535 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate + Calcium
Number of subjects: 50
Study 11269535 — intervention group
Group type: COMPARATOR
Intervention: Only Calcium
Number of subjects: 50
Study 11269535 — intervention group
Group type: COMPARATOR
Intervention: Alendronate + Calcium (Control Group)
Number of subjects: 50
Study 9437184 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg daily soy isoflavones (45 mg genistein)
Number of subjects: 21
Study 9437184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7506165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0
Study 7506165 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 2825745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 150/200 mg single doses
Number of subjects: 18
Study 2825745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 150/200 mg multiple doses (twice daily for 11 days)
Number of subjects: 18
Study 2825745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (various doses)
Number of subjects: 18
Study 2825745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (150/200 mg)
Number of subjects: 18
Study 29250152 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic lumbar discectomy
Number of subjects: 110
Study 29250152 — intervention group
Group type: COMPARATOR
Intervention: Traditional open discectomy
Number of subjects: 110
Study 28516835 — intervention group
Group type: EXPERIMENTAL
Intervention: CATS intervention (Cooperative Cross-Age Teaching)
Number of subjects: 41
Study 28516835 — intervention group
Group type: EXPERIMENTAL
Intervention: CATS intervention (6 hr)
Number of subjects: 41
Study 28516835 — intervention group
Group type: EXPERIMENTAL
Intervention: CATS intervention
Number of subjects: 41
Study 25711321 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of ART
Number of subjects: 4685
Study 25711321 — intervention group
Group type: COMPARATOR
Intervention: Deferred initiation of ART
Number of subjects: 4685
Study 23865122 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 80
Study 23865122 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 80
Study 20947492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 42
Study 20947492 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched therapeutic exercise (DMTE)
Number of subjects: 42
Study 20947492 — intervention group
Group type: EXPERIMENTAL
Intervention: CST atrophy
Number of subjects: 42
Study 20947492 — intervention group
Group type: EXPERIMENTAL
Intervention: VLSM
Number of subjects: 42
Study 18318731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) with compression handpiece
Number of subjects: 10
Study 18318731 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 10
Study 18318731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 10
Study 17174807 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk group (n = 139)
Number of subjects: 289
Study 17174807 — intervention group
Group type: COMPARATOR
Intervention: First quartile of CHD risk
Number of subjects: 289
Study 17174807 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 289
Study 17174807 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR
Number of subjects: 289
Study 12713612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis (CMA)
Number of subjects: 0
Study 10945091 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in systolic blood pressure among hypertensives
Number of subjects: 387
Study 10945091 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake
Number of subjects: 387
Study 9198262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month dynamic peripheral training programme
Number of subjects: 24
Study 9198262 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1347857 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion at 0.6 micrograms/min for 4 hours, then up to a maximum of 10 days
Number of subjects: 117
Study 1347857 — intervention group
Group type: COMPARATOR
Intervention: Standard best management (control)
Number of subjects: 117
Study 1347857 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 117
Study 2988107 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g coarse wheat bran
Number of subjects: 20
Study 2988107 — intervention group
Group type: COMPARATOR
Intervention: 30 g placebo bran
Number of subjects: 20
Study 31257439 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation changes associated with prenatal smoking
Number of subjects: 412
Study 31257439 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent samples from different stages across the life course
Number of subjects: 412
Study 30353049 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy including manual lymphatic drainage (T+MLD)
Number of subjects: 77
Study 30353049 — intervention group
Group type: COMPARATOR
Intervention: Complete Decongestive Therapy without manual lymphatic drainage (T-MLD)
Number of subjects: 77
Study 26739979 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures with cusped teeth
Number of subjects: 20
Study 26739979 — intervention group
Group type: COMPARATOR
Intervention: Overdentures with cuspless teeth
Number of subjects: 20
Study 24154667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (LRZ; 0.01 mg/kg)
Number of subjects: 27
Study 24154667 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study 22198049 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) plus l-carnitine, celecoxib, and antioxidants (arm 1)
Number of subjects: 104
Study 22198049 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) alone (arm 2)
Number of subjects: 104
Study 22198049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 104
Study 20709257 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A1 (15-minute smoking-cessation and 3-minute NRT adherence counseling at baseline, 1 week, and 4 weeks with free NRT for 2 weeks)
Number of subjects: 719
Study 20709257 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A2 (same as A1 but without adherence counseling)
Number of subjects: 719
Study 20709257 — intervention group
Group type: COMPARATOR
Intervention: Group B (10 minutes of quitting advice)
Number of subjects: 719
Study 20709257 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A1 and A2 (combined intervention groups)
Number of subjects: 719
Study 20709257 — intervention group
Group type: COMPARATOR
Intervention: Group B (control group)
Number of subjects: 719
Study 20709257 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported quitting at 6 months
Number of subjects: 719
Study 17385970 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparation for surgery
Number of subjects: 80
Study 17385970 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study 15749505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radio frequency ablation
Number of subjects: 126
Study 15749505 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 126
Study 17984132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1 x 10(6) cells/0.1 mL, n = 9)
Number of subjects: 28
Study 17984132 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (2 x 10(6) cells/0.1 mL, n = 10)
Number of subjects: 28
Study 17984132 — intervention group
Group type: COMPARATOR
Intervention: Control (0.1 mL autologous plasma/injection, n = 9)
Number of subjects: 28
Study 11070964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 60
Study 11070964 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study 8853730 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus Lamivudine (3TC)
Number of subjects: 0
Study 8853730 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study 1518699 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-culture method
Number of subjects: 70
Study 6438683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (800 mg/day)
Number of subjects: 50
Study 6438683 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ) (400 mg/day)
Number of subjects: 50
Study 6438683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrations of sulpiride or CPZ
Number of subjects: 50
Study 6438683 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrations of sulpiride or CPZ
Number of subjects: 50
Study 31256717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP goal (below 120 mm Hg)
Number of subjects: 9358
Study 31256717 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP goal (below 140 mm Hg)
Number of subjects: 9358
Study 31256717 — intervention group
Group type: EXPERIMENTAL
Intervention: High medication burden
Number of subjects: 9358
Study 31256717 — intervention group
Group type: COMPARATOR
Intervention: Intensive vs Standard treatment
Number of subjects: 9358
Study 31256717 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication burden
Number of subjects: 9358
Study 29744647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow grafting (percutaneous mesenchymal cell injection)
Number of subjects: 125
Study 29744647 — intervention group
Group type: COMPARATOR
Intervention: Core decompression (CD)
Number of subjects: 125
Study 29744647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow injection
Number of subjects: 125
Study 27071759 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (55 mg/day, range 40-60 mg/day)
Number of subjects: 63
Study 27071759 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (146 mg/day, range 50-200 mg/day)
Number of subjects: 63
Study 24696860 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 LPM oxygen via a nasal cannula
Number of subjects: 340
Study 24696860 — intervention group
Group type: COMPARATOR
Intervention: Room air only
Number of subjects: 340
Study 22459699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 203
Study 22459699 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFCs)
Number of subjects: 203
Study 22459699 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD)
Number of subjects: 203
Study 22459699 — intervention group
Group type: COMPARATOR
Intervention: Sham interventions (TENS sham, IFCs sham, SWD sham)
Number of subjects: 203
Study 20202239 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day for 8 weeks
Number of subjects: 59
Study 20202239 — intervention group
Group type: COMPARATOR
Intervention: Circumcision
Number of subjects: 59
Study 17907109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.5 mg
Number of subjects: 568
Study 17907109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 568
Study 17907109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar
Number of subjects: 568
Study 16150142 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures ANOVA
Number of subjects: 0
Study 16150142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level analysis
Number of subjects: 0
Study 16150142 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional analysis
Number of subjects: 0
Study 16150142 — intervention group
Group type: COMPARATOR
Intervention: Complete case analysis
Number of subjects: 0
Study 11821087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 172
Study 11821087 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy
Number of subjects: 172
Study 10721039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 10721039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 0
Study 7726526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin 2 g every 4 hours and Gentamicin 1.5 mg/kg every 8 hours for 2 weeks (Group A)
Number of subjects: 7
Study 7726526 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 10 mg/kg/12 hours on days 1-3, 6 mg/kg/12 hours on days 4-7, and 7 mg/kg/24 hours on day 8 (Group B)
Number of subjects: 7
Study 30268346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) promethazine
Number of subjects: 170
Study 30268346 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) Ondansetron
Number of subjects: 170
Study 28122337 — intervention group
Group type: EXPERIMENTAL
Intervention: tivantinib
Number of subjects: 98
Study 28122337 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study 28122337 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR > 3
Number of subjects: 98
Study 28122337 — intervention group
Group type: EXPERIMENTAL
Intervention: vascular invasion
Number of subjects: 98
Study 28122337 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR status
Number of subjects: 98
Study 28122337 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 98
Study 26458508 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVIE en santé (n=375)
Number of subjects: 750
Study 26458508 — intervention group
Group type: COMPARATOR
Intervention: Websites (n=375)
Number of subjects: 750